drugset / Trial / NCT05240131
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Phase 1/2
Unknown
88 enrolled
Galecto Biotech AB
Hoffmann-La Roche · collabLinical Europe GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is an open label study followed by a randomised, double-blind, placebo-controlled, parallel group and an extension study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2022-03-15
- Primary completion
- 2024-05-30
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selvigaltin | Small molecule | 100 mg | Oral |
| Subject | Selvigaltin | Small molecule | 200 mg | Oral |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |